SCHEMBL287646

SCHEMBL287646

CCC(c1ccc(C(N)=O)c(F)c1C(O)c1c[nH]c2ncncc12)S(=O)(=O)O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 11/20 0.33
AKT1 P31749 7/20 0.33
HTR1A P08908 2/20 0.33
HTR7 P34969 2/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
KCNH2 Q12809 1/20 0.32
ATM Q13315 1/20 0.32
BMPR1B O00238 1/20 0.31
PLK4 O00444 1/20 0.31
PIR O00625 1/20 0.31
AURKA O14965 1/20 0.31
DCLK1 O15075 1/20 0.31
EPHB6 O15197 1/20 0.31
RIPK2 O43353 1/20 0.31
STK16 O75716 1/20 0.31
OXSR1 O95747 1/20 0.31
MAP4K4 O95819 1/20 0.31
ABL1 P00519 1/20 0.31
RAF1 P04049 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415659 0.87 BRAF (0.34) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL287953 0.83 CYP2C9 (0.42) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL3700070 0.82 RPS6KB1 (0.39) RPS6KB1AKT1HTR1AHTR7
SCHEMBL298762 0.77 PDPK1 (0.32) CYP3A4PLK4AURKAMAP4K4FES
SCHEMBL3709679 0.74 RPS6KB1 (0.37) RPS6KB1AKT1PLK4AURKADCLK1
SCHEMBL285511 0.74 BRAF (0.44) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL995687 0.74 BRAF (0.56) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL994632 0.73 BRAF (0.45) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL297931 0.72 BRAF (0.43) CYP3A4CYP2C9BMPR1BPLK4PIR
SCHEMBL413438 0.72 BRAF (0.45) CYP3A4CYP2C9BMPR1BPLK4PIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153641-B2 Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf PLEXXIKON INC. (US) 2012-04-10 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
US-20090286783-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286783-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, PRKACA, RAF1 RPS6KB1 478/4885AKT1 35/4885HTR1A 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.